본문 바로가기
KERD
논문KCI 등재

해외 주요 국가의 5-11세 소아 코로나19 예방접종 정책 동향

Latest Overseas Policy on Coronavirus Disease 2019 Vaccination for Children Aged 5 to 11

최윤영|최영준|문지현
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)|2022.04|Pediatric Infection and Vaccine|제29권 제1호|pp. 16-27|DOI 10.14776/piv.2022.29.e5

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

ChildrenSARS-CoV-2VaccinesCoronavirus disease 2019

초록

우리 나라는 2022년 3월에 5–11세 소아의 코로나19 예방접종을 시작하였다. 5–11세 소아에서 중증 코로나19가 발생할 위험은 높지 않기 때문에, 이 연령에 대한 코로나19 예방접종 정책은 각 국가의 상황에 따라 상이하다. 본 논문에서는 해외 주요국가의 5–11세 소아 코로나19 예방접종 관련 정책을 살펴보고, 5–11세 코로나19 예방접종을 시작하는 우리 나라에서 고려할사항에 대하여 언급하였다.

Abstract

In Korea, children aged 5 to 11 have been vaccinated against coronavirus disease 2019 (COVID-19) from March 2022. Due to this age group not being at a high risk of developing severe COVID-19 symptoms, each major country has different, circumstance dependent, immunization policies for children. In this review, the COVID-19 vaccination policies for 5–11 years old children in major countries were reviewed and considerations were presented for Korea, where children 5–11 years old are starting to get vaccinated against COVID-19.

참고문헌 (51)

  1. Forrest CB, "Severity of acute COVID-19 in children <18 years old March 2020 to December 2021", Pediatrics, 149, pp.e2021055765~ (2022)
  2. Sorg AL, "Risk of hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany", medRxiv, ~ (2021)
  3. Hyunju Lee, "Analysis of Critical COVID-19 Cases Among Children in Korea", Journal of Korean Medical Science, 37(1), pp.1~10 (2022), 대한의학회[DOI]
  4. "COVID-19 vaccination guide - for children 5-11 years old" (2022)[URL]
  5. Woodworth KR, "The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years-United States, November 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1579~1583 (2021)
  6. "Benefits-risks of Pfizer-BioNTech COVID-19 vaccine for ages 5 to 11 years" (2021)[URL]
  7. Committee on Infectious Diseases, "COVID-19 vaccines in children and adolescents", Pediatrics, 149, pp.e2021054332~ (2022)
  8. "IDSA and PIDS support authorization of pediatric COVID-19 vaccine" (2021)[URL]
  9. "COVID-19 vaccine safety updates: Primary series in children and adolescents ages 5–11 and 12–15 years, and booster doses in adolescents ages 16–24 years" (2022)[URL]
  10. Hause AM, "COVID-19 vaccine safety in children aged 5–11 years-United States, November 3-December 19, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1755~1760 (2021)
  11. "Children and COVID-19 vaccination trends" (2022)[URL]
  12. "Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11" (2021)[URL]
  13. "Interim public health considerations for COVID-19 vaccination of children aged 5-11 years" (2021)[URL]
  14. "AIFA approves Comirnaty vaccine for ages 5 to 11" (2021)[URL]
  15. Esposito S, "Pediatricians of Emilia-Romagna Region, Italy. Manifesto of the pediatricians of Emilia-Romagna region, Italy, in favor of vaccination against COVID in children 5-11 years old", Ital J Pediatr, 48, pp.40~ (2022)
  16. "Ministero della Salute. Report vaccini anti COVID-19" (2022)[URL]
  17. Vygen-Bonnet S, "STIKO-Empfehlung zur COVID-19-Impfung von Kindern im alter von 5–11 Jahren mit dem mRNA-impfstoff comirnaty und die dazugehörige wissenschaftliche Begründung", Epidemiol Bull, 1, pp.16~47 (2022)
  18. "Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 31.12.2021" (2022)[URL]
  19. "Aktueller impfstatus" (2022)[URL]
  20. "Stratégie de vaccination contre la Covid-19 – Place du vaccin à ARNm COMIRNATY® chez les 5-11 ans" (2021)[URL]
  21. "Foire aux questions: la vaccination des enfants" (2021)[URL]
  22. "Le tableau de bord de la vaccination" (2021)[URL]
  23. "JCVI statement on COVID-19 vaccination of children and young people: 22 December 2021" (2021)[URL]
  24. "JCVI statement on vaccination of children aged 5 to 11 years old" (2022)[URL]
  25. "CO-CIN: child admissions and severity by epoch CO-CIN update January 2022, 6 January 2022" (2022)[URL]
  26. "COVID-19 response: living with COVID-19" (2022)[URL]
  27. "ATAGI recommendations on Pfizer COVID-19 vaccine use in children aged 5 to 11 years" (2021)[URL]
  28. "ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years" (2022)[URL]
  29. "Pfizer COVID-19 vaccine safety data - child participants" (2021)[URL]
  30. "HSA extends the use of comirnaty COVID-19 vaccine by Pfizer-BioNTech to children of ages 5 to 11" (2022)[URL]
  31. "Preparing for the Omicron variant" (2021)[URL]
  32. "Expert Committee on COVID-19 Vaccination Recommends using the paediatric dose Pfizer-BioNTech/Comirnaty vaccine for children aged 5–11 years and extending booster vaccination to persons aged under 30 years" (2021)[URL]
  33. "Vaccination statistics" (2021)[URL]
  34. "Consensus interim recommendations on the use of COVID-19 vaccines in children in Hong Kong (As of 17 January 2022)" (2022)[URL]
  35. "Consensus interim recommendations on the use of COVID-19 vaccines in Hong Kong (As of 25 February 2022)" (2022)[URL]
  36. "Consensus interim recommendations on the use of COVID-19 vaccines in persons with previous COVID-19 infection and children in Hong Kong (as of 12 March 2022)" (2022)[URL]
  37. "Hong Kong vaccination dashboard" (2022)[URL]
  38. "PMDA’s efforts to combat COVID-19" (2021)[URL]
  39. "Effects of the novel coronavirus vaccine on children aged 5 to 11 years" (2022)[URL]
  40. "Report on special approval" (2022)[URL]
  41. "COVID-19 vaccines" (2021)[URL]
  42. "Taiwan to hold off vaccinating 5-11-year-olds against COVID-19" (2022)[URL]
  43. "Coronavirus (COVID-19), Republic of Korea" (2022)[URL]
  44. Mensah AA, "Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England", Lancet Child Adolesc Health (2022)
  45. Long QX, "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections", Nat Med, 26, pp.1200~1204 (2020)
  46. McDade TW, "Low levels of neutralizing antibodies after natural infection with severe acute respiratory syndrome coronavirus 2 in a community-based serological study", Open Forum Infect Dis, 9 (2022)
  47. Dorabawila V, "Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant", medRxiv, ~ (2022)
  48. Buchan SA, "Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes", medRxiv, ~ (2022)
  49. Klein NP, "Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years-VISION Network, 10 States, April 2021-January 2022", MMWR Morb Mortal Wkly Rep, 71, pp.352~358 (2022)
  50. Levy M, "Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France", JAMA, 327, pp.281~283 (2022)
  51. Zambrano LD, "Effectiveness of BNT162b2(Pfizer-BioNTech)mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years-United States, July-December 2021", MMWR Morb Mortal Wkly Rep, 71, pp.52~58 (2022)

관련 논문AI추천

COVID-19 백신의 소아 접종: 우리는 무엇을 준비해야 하는가?박소연(재) 국가생명윤리정책원 · 생명, 윤리와 정책2021 · 제5권 제2호5-11세 소아에서 코로나19 백신의 효능 및 안전성에 대한 체계적 문헌고찰유수연, 정채림, 최미영, 최수한, 최영준대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호국내 5-11세 소아의 코로나19 백신 접종에 대한 델파이 연구이영화, 최영준, 최재홍대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호코로나바이러스 감염증-19 백신에 대한 업데이트 및 소아청소년에서의 고려사항Choi Eun Hwa, Kang Hyun Mi, Kim Yae-Jean대한소아감염학회 · Pediatric Infection and Vaccine2021 · 제28권 제1호Clinical Manifestations, Epidemiologic Characteristics, and Disease Burden of the Coronavirus Disease-19 in Children Ages 5-11 Years Old박지영, Choe Young June, Kang Hyun Mi대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제2호소아청소년 코로나바이러스감염증-19 대응지침김기환, 김동현, 김종현, 김한울, 박지영, 은병욱, 조대선, 조은영, 최수한, 최은화, 최재홍, 한미선, 대한소아감염학회대한소아감염학회 · Pediatric Infection and Vaccine2020 · 제27권 제1호

이 간행물의 다른 논문 (5건)

소아청소년 코로나바이러스감염증-19의 치료: 치료 약제를 중심으로최재홍, 최수한, 윤기욱pp. 1-155-11세 소아에서 코로나19 백신의 효능 및 안전성에 대한 체계적 문헌고찰정채림, 유수연, 최미영, 최수한, 최영준pp. 28-36국내 5-11세 소아의 코로나19 백신 접종에 대한 델파이 연구최영준, 최재홍, 이영화pp. 37-45Intraventricular Antimicrobial Therapy for Intractable Ventriculitis: Two Case ReportsYoon Yoonsun, Kim Sang-Dae, 이지원, Kim Yun-Kyungpp. 46-53Nontyphoidal Salmonella Meningitis in an Immunocompetent ChildHan Mi Seon, Moon Hye Jeong, Lee Yoonhapp. 54-60
원문 보기